恒瑞医药2025年度利润分配方案及2026年中期分红授权详解

一、报告核心要点

• 每股派息0.2元（含税），以分红派息登记日的股本（扣除回购专用账户股份）为基数。
• 2025年度归属于母公司股东的净利润为77.11亿元，期末合并未分配利润为401.73亿元。
• 2025年度现金分红总额预计为13.26亿元（含税），加上回购股份金额9.78亿元，合计分红及回购金额达23.04亿元，占当年净利润的29.88%。
• 董事会提请股东大会授权，允许董事会制定2026年中期分红方案。
• 分红比例低于30%，主要因创新药及厂区扩建等需大量资金投入。
• 公司分红方案尚需提交2025年度股东大会审议。

二、详细利润分配方案与历史数据

• 2025年度利润分配方案：每10股派发2元现金股利（含税）。
• 截至2026年3月16日，公司总股本为66.37亿股，回购专用账户持有678.77万股不参与分红。
• 实际现金分红总额13.26亿元（含税），以股权登记日回购账户股份为准，或会有所调整。
• 2025年度回购股份金额为9.78亿元，现金分红+回购总额为23.04亿元，占净利润29.88%。
• 如公司总股本在分红前发生变动，将保持每股派息比例不变，总分红金额做相应调整并公告。
• 公司近三年累计现金分红38.74亿元，近三年分红比例63.33%，未触及监管红线。

三、分红比例低于30%的原因

• 医药行业为高投入、高风险行业，创新药研发需大量长期资金。
• 公司正处于仿制药向创新药转型关键期，资金需求大。
• 广东、北京、天津等地新建及扩建厂区，需大量投资。
• 加大与国际研发机构合作，推进全球化创新药布局，资金需求高。

四、2026年中期分红授权方案

• 股东大会拟授权董事会在符合利润分配条件下，制定2026年中期分红方案。
• 中期分红的前置条件包括：报告期盈利、母公司未分配利润为正、现金流充裕且符合上交所、港交所等分红相关规定。
• 中期分红金额上限为相应期间归属于股东的净利润。
• 2026年3月25日董事会全票通过利润分配及中期分红授权议案，尚需年度股东大会审议通过。

五、对投资者和股价的潜在影响

• 分红方案显示公司保持稳定分红，强化投资者回报信心。
• 分红比例低于30%属行业与发展阶段特殊需求，短期或引发市场对资金使用效率与研发投入的关注。
• 持续的高研发投入及全球化创新药布局，有望为公司中长期成长奠定基础，但短期现金分红水平偏低，可能对部分偏好高分红的投资者持谨慎态度。
• 公司净利润持续增长，资金实力雄厚，分红政策调整空间大，预示公司有能力应对未来行业竞争及新项目投资。
• 此次分红和回购金额合计占净利润近三成，显示公司对股东回报的重视。
• 若后续分红政策进一步优化或创新药业务取得突破，有望对公司股价形成积极影响。

六、风险提示

• 本次分红方案仍需提交股东大会审议，尚未最终落地。
• 高额研发投入及持续扩建或对未来现金流形成压力。
• 分红比例低于部分投资者预期，或引发短期市场波动。

七、结语

恒瑞医药2025年度分红方案尽管分红比例相对较低，但显示公司对创新药及国际化布局的坚定投入，既反映成长潜力，也提醒投资者关注短期分红水平与长期增长之间的平衡。建议投资者密切关注公司后续年度股东大会表决结果及创新药业务进展。

免责声明： 本文仅为公开信息整理和解读，不构成任何投资建议或买卖依据。投资者应根据自身风险承受能力，理性决策，注意投资风险。

English Version

Hengrui Pharma 2025 Dividend Plan and 2026 Interim Dividend Authorization – Detailed Analysis

1. Key Highlights

• Dividend per share: RMB 0.2 (pre-tax), based on shares outstanding (excluding treasury shares) on the record date.
• Net profit attributable to parent for 2025: RMB 7.71 billion; end-period undistributed profit: RMB 40.17 billion.
• Total cash dividend for 2025 estimated at RMB 1.326 billion (pre-tax); combined with share repurchase of RMB 978 million, total cash outflow for dividend and buyback is RMB 2.304 billion, 29.88% of annual net profit.
• Board proposes shareholder authorization for the board to formulate the 2026 interim dividend plan.
• The low dividend payout (<30%) is attributed to high R&D and expansion capex.
• The dividend plan is pending approval at the 2025 Annual General Meeting.

2. Dividend Plan Details and Historical Data

• 2025 plan: RMB 2 cash dividend for every 10 shares (pre-tax).
• As of March 16, 2026, total shares: 6.637 billion; treasury shares: 6.787 million (not eligible for dividend).
• Actual cash dividend total: RMB 1.326 billion (pre-tax), subject to adjustment on record date.
• 2025 share repurchase: RMB 978 million; total cash outflow for dividend and buyback: RMB 2.304 billion (29.88% payout ratio).
• Dividend ratio and amount will be adjusted if total shares change before the record date.
• Cumulative cash dividends over three years: RMB 3.874 billion; payout ratio: 63.33%; well above regulatory minimums.

3. Reasons for Dividend Payout Below 30%

• Pharmaceutical industry is capital and risk intensive, with long R&D cycles for innovative drugs.
• Company is in a critical transition from generics to innovative drugs, requiring significant funding.
• New and expanded manufacturing sites in Guangdong, Beijing, Tianjin demand large investments.
• Increased cooperation with international R&D institutions for global competitiveness and innovation pipeline.

4. 2026 Interim Dividend Authorization

• Shareholder meeting to authorize board to set 2026 interim dividend plan, within profit distribution conditions.
• Prerequisites: profitability, positive retained earnings, sufficient cash flow, compliance with listing rules (SHSE, HKEX, etc.).
• Interim dividend cap: not to exceed net profit attributable to shareholders for the period.
• Plan approved unanimously by the board on March 25, 2026, pending AGM approval.

5. Potential Market & Shareholder Impact

• Dividend policy signals stable payout and investor returns.
• The sub-30% payout reflects strategic R&D and capex needs, potentially raising short-term concerns on capital efficiency and cash use.
• High R&D and global innovation investment suggest long-term growth potential, but lower cash payout may temper sentiment among yield-focused investors.
• Solid profit and cash reserves indicate capacity for future investments and dividend flexibility.
• Dividend plus buyback at nearly 30% of profits reflects strong shareholder return focus.
• Further policy enhancements or innovative drug breakthroughs could positively impact share price.

6. Risks and Warnings

• Dividend plan pending AGM approval; not yet finalized.
• High R&D and capex could pressure future cash flows.
• Payout ratio below some investor expectations, possibly triggering short-term volatility.

7. Conclusion

Hengrui Pharma’s 2025 dividend plan, though with a relatively low payout, reflects its strong commitment to R&D and global expansion. This balances short-term dividend returns with long-term growth prospects. Investors should closely monitor AGM resolutions and the company’s progress in innovative drug development.

Disclaimer: This article is for information purposes only and does not constitute investment advice. Investors should make decisions based on their risk tolerance and conduct their own due diligence.

View 恒瑞医药 Historical chart here